2023
Selected-Lesion SRS as a Novel Strategy in Treatment of Patients with Multiple Brain Metastases
Singh C, Theriault B, An Y, Yu J, Knisely J, Shepard M, Wegner R, Warnick R, Peker S, Samanci Y, Trifiletti D, Lee C, Yang H, Bernstein K, Kondziolka D, Tripathi M, Mathieu D, Mantziaris G, Pikis S, Sheehan J, Chiang V. Selected-Lesion SRS as a Novel Strategy in Treatment of Patients with Multiple Brain Metastases. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: e150-e151. DOI: 10.1016/j.ijrobp.2023.06.971.Peer-Reviewed Original ResearchWhole-brain radiation therapyTreatment of patientsSystemic diseaseBrain metastasesLesion locationIntracranial lesionsPrior whole-brain radiation therapyMultiple brain metastasesBrain radiation therapyUntreated brain metastasesBrain metastasis treatmentCurrent practice patternsSigns/symptomsPresence of symptomsMATERIAL/METHODSImmunotherapy optionsSystemic therapyUntreated lesionsMedical oncologyPerilesional edemaDrug optionsClinical trialsPractice patternsClinical indicationsMetastasis treatmentSelected-Lesion Stereotactic Radiosurgery (SL-SRS) as a Novel Strategy in the Treatment of Patients With Multiple Brain Metastases
Theriault B, Singh C, Yu J, Knisely J, Shepard M, Wegner R, Warnick R, Peker S, Samanci Y, Trifiletti D, Lee C, Yang H, Bernstein K, Kondziolka D, Tripathi M, Mathieu D, Mantziaris G, Pikis S, Sheehan J, Chiang V. Selected-Lesion Stereotactic Radiosurgery (SL-SRS) as a Novel Strategy in the Treatment of Patients With Multiple Brain Metastases. Cureus 2023, 15: e45457. PMID: 37859877, PMCID: PMC10583225, DOI: 10.7759/cureus.45457.Peer-Reviewed Original ResearchWhole brain radiotherapyInternational Radiosurgery Research FoundationPrior whole brain radiotherapyBrain metastasesStereotactic radiosurgeryCommon reasonAsymptomatic brain metastasesNon-eloquent locationsSystemic treatment optionsMultiple brain metastasesPoor functional statusTreatment of patientsCentral nervous systemAttributable symptomsExtracranial diseaseSystemic therapyUntreated lesionsMedical oncologySystemic diseaseFunctional statusTreatment optionsClinical trialsSingle lesionLesion locationIntracranial lesions
2021
Systematic review and meta-analysis of radiation therapy for high-risk non-muscle invasive bladder cancer
Rodrigues Pessoa R, Mueller A, Boxley P, Flaig T, Piper C, Konety B, Yu J, Gershman B, Kukreja J, Kim S. Systematic review and meta-analysis of radiation therapy for high-risk non-muscle invasive bladder cancer. Urologic Oncology Seminars And Original Investigations 2021, 39: 786.e1-786.e8. PMID: 33846085, DOI: 10.1016/j.urolonc.2021.03.009.Peer-Reviewed Original ResearchConceptsHigh-risk non-muscle invasive bladder cancerNon-muscle invasive bladder cancerCancer specific-survivalRecurrence-free survivalInvasive bladder cancerBacillus Calmette-GuerinOverall survivalRadiation therapyBladder cancerMeta-analysisRates of recurrence-free survivalClinical trialsGoal of bladder preservationMetastatic disease rateSalvage radical cystectomyCochrane Central Register of Controlled TrialsProspective clinical trialCentral Register of Controlled TrialsTreatment of patientsRegister of Controlled TrialsSystematic reviewCochrane Central RegisterLow-quality evidenceQuality of evidenceBladder preservation
2020
Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19
Zaorsky NG, Yu JB, McBride SM, Dess RT, Jackson WC, Mahal BA, Chen R, Choudhury A, Henry A, Syndikus I, Mitin T, Tree A, Kishan AU, Spratt DE. Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. Advances In Radiation Oncology 2020, 5: 26-32. PMID: 33145460, PMCID: PMC7598436, DOI: 10.1016/j.adro.2020.10.003.Peer-Reviewed Original ResearchProstate cancerM1 diseaseNational Comprehensive Cancer Network risk groupClinical node-positive diseaseFavorable intermediate-risk diseaseRadiation therapy recommendationsIntermediate-risk diseaseNeoadjuvant hormone therapyNode-positive diseaseStage of diseaseTreatment of patientsProstate cancer stageRadiation oncology departmentsGlobal pandemicAdjuvant radiationModerate hypofractionationHormone therapyPositive diseaseRoutine visitsCancer stageTherapy recommendationsOncology departmentRisk groupsRadiation therapyTelemedicine consultationsProstate Cancer Radiation Therapy Recommendations in Response to COVID-19
Zaorsky NG, Yu JB, McBride SM, Dess RT, Jackson WC, Mahal BA, Chen R, Choudhury A, Henry A, Syndikus I, Mitin T, Tree A, Kishan AU, Spratt DE. Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. Advances In Radiation Oncology 2020, 5: 659-665. PMID: 32292839, PMCID: PMC7118610, DOI: 10.1016/j.adro.2020.03.010.Peer-Reviewed Original ResearchProstate cancerM1 diseaseNational Comprehensive Cancer Network risk groupClinical node-positive diseaseFavorable intermediate-risk diseaseRadiation therapy recommendationsIntermediate-risk diseaseNeoadjuvant hormone therapyNode-positive diseaseStage of diseaseTreatment of patientsProstate cancer stageRadiation oncology departmentsGlobal pandemicAdjuvant radiationModerate hypofractionationHormone therapyPositive diseaseRoutine visitsCancer stageTherapy recommendationsOncology departmentRisk groupsRadiation therapyTelemedicine consultations
2016
Disparities in Access and Treatment of Patients With High-Risk Prostate Cancer: Results From a Population-Based Cohort
Wang E, Abouassaly R, Yu J, Meropol N, Cooper G, Shah N, Williams S, Gonzalez C, Smaldone M, Kutikov A, Zhu H, Kim S. Disparities in Access and Treatment of Patients With High-Risk Prostate Cancer: Results From a Population-Based Cohort. International Journal Of Radiation Oncology • Biology • Physics 2016, 96: e258. DOI: 10.1016/j.ijrobp.2016.06.1269.Peer-Reviewed Original ResearchDisparities in Treatment of Patients With High-risk Prostate Cancer: Results From a Population-based Cohort
Wang E, Yu J, Abouassally R, Meropol N, Cooper G, Shah N, Williams S, Gonzalez C, Smaldone M, Kutikov A, Zhu H, Kim S. Disparities in Treatment of Patients With High-risk Prostate Cancer: Results From a Population-based Cohort. Urology 2016, 95: 88-94. PMID: 27318264, DOI: 10.1016/j.urology.2016.06.010.Peer-Reviewed Original ResearchConceptsHigh-risk prostate cancerWatchful waitingRadiation therapyProstate cancerPrimary treatmentTreatment of high-risk prostate cancerOdds ratioNational Cancer Data BaseMultivariate logistic regression analysisTreatment of patientsLogistic regression analysisRadical prostatectomyPrimary therapyCurative therapyPrimary outcomeCancer communityTherapySignificant racial disparitiesAcademic hospitalPatientsBlack menCancerHospitalStudy periodWhite men
2010
Adjuvant radiotherapy after radical prostatectomy: Evidence and analysis
Raldow A, Hamstra D, Kim S, Yu J. Adjuvant radiotherapy after radical prostatectomy: Evidence and analysis. Cancer Treatment Reviews 2010, 37: 89-96. PMID: 20667660, DOI: 10.1016/j.ctrv.2010.07.001.Peer-Reviewed Original ResearchConceptsTarget volumeIncreased risk of cancer recurrencePositive surgical marginsSeminal vesicle invasionTreatment target volumeLocalized prostate cancerRisk of cancer recurrenceSigns of recurrenceTreatment of patientsTechnical aspects of treatmentDecrease side effectsRandomized clinical trialsUndetectable PSAAdjuvant radiotherapyAdjuvant settingDose escalationExtracapsular extensionRadical prostatectomySurgical marginsRadiation therapyProstate cancerPathological examinationClinical outcomesCure rateCancer recurrence